Search

Your search keyword '"Holderried, Tobias A."' showing total 242 results

Search Constraints

Start Over You searched for: Author "Holderried, Tobias A." Remove constraint Author: "Holderried, Tobias A."
242 results on '"Holderried, Tobias A."'

Search Results

1. ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

3. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

4. Whole body irradiation with intensity-modulated helical tomotherapy prior to haematopoietic stem cell transplantation: analysis of organs at risk by dose and its effect on blood kinetics

6. Hospital sanitary facilities on wards with high antibiotic exposure play an important role in maintaining a reservoir of resistant pathogens, even over many years

7. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial

8. Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany

10. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

11. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial

13. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

14. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

15. Optimized Conformal Total Body Irradiation with VMAT Using a Linear-Accelerator-Based Radiosurgery Treatment System in Comparison to the Golden Standard Helical TomoTherapy

16. P1387: TREATMENT WITH A LEUKEMIA-DERIVED DENDRITIC CELL VACCINE INDUCES INNATE AND ADAPTIVE IMMUNE RESPONSE CORRELATING WITH CLINICAL RESPONSE IN AML PATIENTS IN CR1 WITH MEASURABLE RESIDUAL DISEASE

18. Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome

21. Evaluation of factors associated with survival in allogeneic stem cell-transplanted patients admitted to the intensive care unit (ICU).

24. Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

25. Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

26. The Potential of E-Health in Patients after Allogeneic Stem Cell Transplantation

27. 713 The PRAME opportunity – high peptide copy numbers, homogenous expression and high prevalence to address a broad patient population across different solid cancers with TCR-based therapeutics

28. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

31. On-demand erythrocyte disposal and iron recycling requires transient macrophages in the liver

32. The Potential of E-Health in Patients after Allogeneic Stem Cell Transplantation

33. Peripheral blood kinetics following total body irradiation and allogeneic hematopoietic stem cell transplantation: Timing matters.

36. Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

37. Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival

38. Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

39. 959 Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial

44. Fecal microbiota transfer for refractory intestinal graft‐versus‐host disease — Experience from two German tertiary centers

45. Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility

46. sj-pdf-2-lup-10.1177_0961203321999723 - Supplemental material for Helios-expressing CD8+ T cells are decreased in patients with systemic lupus erythematosus

47. sj-pdf-1-lup-10.1177_0961203321999723 - Supplemental material for Helios-expressing CD8+ T cells are decreased in patients with systemic lupus erythematosus

48. sj-docx-1-tab-10.1177_1759720X211006963 – Supplemental material for Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis

49. sj-docx-2-tab-10.1177_1759720X211006963 – Supplemental material for Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis

50. Fecal microbiota transfer for refractory intestinal graft-versus-host disease - Experience from two German tertiary centers

Catalog

Books, media, physical & digital resources